| epirubicin / Generic mfg. |
NCT00193024: Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer |
|
|
| Terminated | 2 | 90 | US | Docetaxel, Epirubicin | SCRI Development Innovations, LLC, Aventis Pharmaceuticals, Pharmacia and Upjohn | Breast Cancer | 10/03 | 10/04 | | |
NCT00620100: To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent |
|
|
| Terminated | 2 | 2 | Europe | Docetaxel | Sanofi | Breast Neoplasms | 04/05 | 04/05 | | |
NCT00004237: Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer |
|
|
| Completed | 2 | | Europe | cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride, mitoxantrone hydrochloride, vinorelbine tartrate, conventional surgery, radiation therapy | Royal Marsden NHS Foundation Trust | Breast Cancer | | 09/05 | | |
NCT00378313: A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer |
|
|
| Completed | 2 | 76 | US | gemcitabine, epirubicin, paclitaxel | NSABP Foundation Inc | Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Locally Advanced | | 11/05 | | |
NCT00795899: Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO) |
|
|
| Completed | 2 | 230 | Europe | Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab | German Breast Group, AGO Study Group | Breast Cancer | 12/05 | 09/08 | | |
NCT00645866: Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer |
|
|
| Completed | 2 | 47 | US | capecitabine, docetaxel, epirubicin hydrochloride, laboratory biomarker analysis, pharmacogenomic studies, biopsy, neoadjuvant therapy, therapeutic surgical procedure | Mayo Clinic, National Cancer Institute (NCI) | Breast Cancer | 03/06 | 03/06 | | |
NCT00256360 / 2005-001876-11: Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer |
|
|
| Completed | 2 | 117 | Europe | dose dense with neulasta | Universitaire Ziekenhuizen KU Leuven, St-Augustinus Wilrijk | Breast Cancer | | 05/06 | | |
NCT00286819: Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer |
|
|
| Completed | 2 | 50 | Europe | the FEC75 and 95 regimen | Central European Cooperative Oncology Group | Breast Cancer | | 09/06 | | |
NCT00072319: Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer |
|
|
| Completed | 2 | | US | filgrastim, cyclophosphamide, epirubicin hydrochloride, paclitaxel, adjuvant therapy, neoadjuvant therapy | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Pharmacia, Amgen | Breast Cancer | 11/06 | 11/06 | | |
NCT00110695: Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer |
|
|
| Completed | 2 | 66 | US | Nanoparticle albumin bound paclitaxel followed by FEC | NSABP Foundation Inc, Celgene Corporation | Breast Neoplasms | 12/06 | 07/08 | | |
NCT00239343: Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer |
|
|
| Completed | 2 | 160 | Europe | gefitinib | AstraZeneca | Breast Cancer | 05/07 | 05/07 | | |
NCT00242203: Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer |
|
|
| Completed | 2 | 120 | US | Zometa, Zoledronic acid, Epirubicin, Ellence, Docetaxel, Taxotere, Trastuzumab, Herceptin, External beam radiation, Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection | Washington University School of Medicine, Novartis, Pfizer | Breast Neoplasms | 08/07 | 05/11 | | |
ETCat01, NCT00527449: Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel |
|
|
| Completed | 2 | 50 | Europe | Epirubicin, Carboplatin, Docetaxel | Klinikum Weissenfels | Primary Breast Cancer | 09/08 | 09/08 | | |
TOP, NCT00162812: Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin |
|
|
| Terminated | 2 | 338 | Europe | Epirubicin | Jules Bordet Institute, Gustave Roussy, Cancer Campus, Grand Paris, Centre Paul Strauss, Centre Hospitalier du Luxembourg, Clinique Louis Cathy - Baudour - Belgium, HIS - Site Etterbeek - Ixelles - Belgium, Clinique Saint Pierre Ottignies, Clinique Ste Elisabeth - Namur - Belgium, University Hospital of Crete, Feculdade de Medicina da Universidade de Sao Paulo - Brasil | Breast Cancer | 12/08 | 04/09 | | |
NCT02307227: Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors |
|
|
| Completed | 2 | 46 | Europe | Trastuzumab, Paclitaxel, Epirubicin, Docetaxel | Centro di Riferimento Oncologico - Aviano | Breast Neoplasms | 04/09 | 04/14 | | |
NCT00176488: Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer |
|
|
| Terminated | 2 | 31 | US | epirubicin, epirubicin hydrochloride, vinorelbine, vinorelbine ditartrate | University of Medicine and Dentistry of New Jersey, National Cancer Institute (NCI) | Breast Cancer | 10/09 | 10/09 | | |
| Completed | 2 | 40 | Europe | 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid | Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield | Breast Cancer | 01/10 | 01/10 | | |
NCT00604435: Neoadjuvant Endostatin and Chemotherapy for Breast Cancer |
|
|
| Completed | 2 | 69 | RoW | docetaxel and epirubicin, docetaxel, Sanofi-Aventis, epirubicin, Pfizer, docetaxel and epirubicin plus endostatin, recombinant human endostatin, Simcere Co. China | Xijing Hospital | Breast Cancer | 01/10 | 01/10 | | |
| Completed | 2 | 100 | US | Trastuzumab, Paclitaxel, FEC75, Lapatinib | GlaxoSmithKline | Neoplasms, Breast | 10/10 | 08/15 | | |
|
ELATE, NCT01205217: Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer |
|
|
| Withdrawn | 2 | 0 | Europe | Lapatinib, Trastuzumab, Epirubicin, Cyclophosphamide, Paclitaxel | GlaxoSmithKline | Neoplasms, Breast | 12/10 | 12/10 | | |
| Terminated | 2 | 6 | US | VPA FEC100 | University of California, San Francisco, H. Lee Moffitt Cancer Center and Research Institute | Breast Cancer | 12/10 | 07/11 | | |
| Completed | 2 | 225 | Canada, Europe, RoW | Pertuzumab, Perjeta, Trastuzumab, Herceptin, FEC, Docetaxel, TCH | Hoffmann-La Roche | Breast Cancer | 06/11 | 01/16 | | |
|
|
|
|
|
|
GIM9, NCT00751868: FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC |
|
|
| Completed | 2 | 47 | Europe | Ixabepilone, Ixempra | Consorzio Oncotech | Breast Cancer | 07/11 | 07/11 | | |
|
NCT00270894: Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients |
|
|
| Completed | 2 | 30 | US | epirubicin, Ellence®, cyclophosphamide, Cytoxan, docetaxel, Taxotere®, trastuzumab, Herceptin® | Accelerated Community Oncology Research Network, Aventis Pharmaceuticals | Breast Neoplasm | 08/11 | 08/11 | | |
| Completed | 2 | 36 | Europe | Nexavar (Sorafenib) | German Breast Group, Bayer | Breast Cancer | 09/11 | 12/11 | | |
| Completed | 2 | 102 | Europe | Epirubicin, Ellence, Pharmorubicin, Cyclophosphamide, Cytoxan, Neosar, Endoxan, Docetaxel, Taxotere, Lapatinib, Tykerb, Trastuzumab, Herceptin | Spanish Breast Cancer Research Group, GlaxoSmithKline | Breast Cancer | 12/11 | 12/13 | | |
|
|
NCT00431795: Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer |
|
|
| Terminated | 2 | 100 | Europe | Pegylated liposomal doxorubicin (Caelyx), Caelyx, Epirubicin, Farmorubicine | Hellenic Oncology Research Group, University Hospital of Crete | Breast Cancer | 06/12 | 06/12 | | |
NCT02119715: A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy |
|
|
| Completed | 2 | 182 | RoW | Pegylated rhG-CSF 100μg/kg, HHPG-19K 100µg/kg, Pegylated rhG-CSF:150 μg/kg, HHPG-19K 150μg/kg, rhG-CSF 5 μg/kg/day, Jie Xin 5 μg/kg/day | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer, Neutropenia, Febrile Neutropenia | 08/12 | 12/12 | | |
| Completed | 2 | 18 | Europe | EndoTAG-1, Non applicable | Jules Bordet Institute | Breast Cancer | 09/12 | 11/12 | | |
NCT01301040: Early Cardiac Toxicity of Adjuvant CT in Elderly BC. |
|
|
| Terminated | 2 | 2 | Europe | epirubicin, cyclophosphamide, docetaxel, Docetaxel: Taxotere, Cyclophosphamide: Endoxan, Epirubicin: Epirubicin Teva | Jules Bordet Institute, Sanofi | Breast Cancer | 03/13 | 03/16 | | |
NCT02225652 / 2010-020772-38: A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer. |
|
|
| Completed | 2 | 11 | Europe | FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Women With Primary Breast Cancer | 09/13 | 07/14 | | |
NCT00756470: Phase II Neoadjuvant in Inflammatory Breast Cancer |
|
|
| Terminated | 2 | 15 | US | Lapatinib, Tykerb, GW572016, Paclitaxel, Taxol, 5-Fluorouracil (5-FU), 5-FU, Adrucil, Efudex, Epirubicin, Cyclophosphamide, Cytoxan, Neosar | M.D. Anderson Cancer Center, GlaxoSmithKline | Breast Cancer | 10/13 | 10/13 | | |
DAFNE, NCT01594177 / 2011-004704-38: Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy |
|
|
| Completed | 2 | 65 | Europe | Afatinib, Trastuzumab, HERCEPTIN, Paclitaxel, Epirubicin, Cyclophosphamide | German Breast Group, Boehringer Ingelheim | Unilateral HER2 Positive Breast Cancer | 03/14 | 03/14 | | |
|
| Terminated | 2 | 34 | Europe | Bevacizumb, Bevacizumab: 10 mg/kg for up to 8 cycles from date of first dose, (cycle repeated every two weeks), 5-Fluorouracil, 5-Fluorouracil: 700mg/m2 for up to 4 cycles from date of first dose, Epirubicin, Epirubicin: 75mg/m2 for up to 4 cycles from date of first dose, Cyclophosphamide, Cyclophosphamide: 700mg/m2 for up to 4 cycles from date of first dose, Docetaxel, Docetaxel: 75mg/m2 for up to 4 cycles from date of first dose | Hellenic Oncology Research Group | Breast Cancer | 04/15 | 04/15 | | |
NCT01740271: A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients |
|
|
| Recruiting | 2 | 48 | Canada | Epirubicin | AHS Cancer Control Alberta | Breast Neoplasms | 06/15 | 06/25 | | |
NCT00379015: Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer |
|
|
| Completed | 2 | 38 | Japan | trastuzumab, cyclophosphamide, docetaxel, epirubicin hydrochloride, conventional surgery, neoadjuvant therapy | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Breast Cancer | 03/16 | 03/16 | | |
| Terminated | 2 | 21 | Europe | Docetaxel, Trastuzumab, Herceptin, Bevacizumab, Avastin, Epirubicin, Cyclophosphamid | West German Study Group, Roche Pharma AG, Sanofi | Breast Cancer | 11/16 | 11/16 | | |
NCT00705315: Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer |
|
|
| Completed | 1/2 | 46 | Europe | Docetaxel, Taxotere, Epirubicin, Farmorubicine, Bevacizumab, Avastin | Hellenic Oncology Research Group | Breast Cancer | 06/10 | 06/10 | | |
|
